[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.150.215. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
From the Food and Drug Administration
December 1, 1999

Review of Generic Bioequivalence Studies

Author Affiliations
 

Not Available

Not Available

JAMA. 1999;282(21):1995. doi:10.1001/jama.282.21.1995-JFD90010-2-1

Questions have been raised recently about the ethics, safety, and effectiveness of generic substitutes for brand-name products. To address this issue, the FDA has examined all 127 in vivo bioequivalence studies in the 273 generic drug applications approved in 1997. The examinations focused on data that are used to evaluate the therapeutic equivalence of a generic and innovator drug.

Three measures were reviewed: the area under the plasma drug concentration–time curve from time 0 to time t (AUC [0-t]), the AUC from time 0 to infinity (AUC [0-Inf]), and the highest drug concentration (Cmax). The observed mean difference between the innovator's product and the generic product for AUC (0-t) was ± 3.47% (SD, 2.84), for AUC (0-Inf) it was ±3.25% (SD, 2.97), and for Cmax it was ± 4.29% (SD, 3.72).

First Page Preview View Large
First page PDF preview
First page PDF preview
×